Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134750 | 0.84 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL12024791 | 0.82 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL12359373 | 0.81 | POLQ (0.47) | PDE2AHCRTR1HCRTR2MKNK1MKNK2 | |
| SCHEMBL13443055 | 0.79 | HCRTR1 (0.57) | HCRTR1HCRTR2 | |
| SCHEMBL10134744 | 0.79 | PDE2A (0.52) | PDE2AMKNK1MKNK2 | |
| SCHEMBL12391550 | 0.77 | MKNK1 (0.54) | PDE2AMKNK1MKNK2ABL1 | |
| SCHEMBL12391556 | 0.77 | CYP2A6 (0.48) | PDE2AMKNK1MKNK2 | |
| SCHEMBL12024786 | 0.77 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL12359369 | 0.76 | CYP2A6 (0.47) | PDE2AMKNK1MKNK2 | |
| SCHEMBL12024774 | 0.76 | PDE2A (0.49) | PDE2AHCRTR1HCRTR2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | PDE2A 2326/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.